{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:20:13Z","timestamp":1791040813641,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The relationship between early changes in biochemical markers of bone turnover and the subsequent BMD response to daily teriparatide therapy in women with postmenopausal osteoporosis was studied. Changes in five biochemical markers, obtained from a subset of women enrolled in the Fracture Prevention Trial, were examined. Early increases in the PICP and the PINP were the best predictors of BMD response to teriparatide in this analysis.<\/jats:p>\n               <jats:p>Introduction: Early reductions in biochemical markers of bone turnover with antiresorptive therapy negatively correlate with subsequent increases in BMD. We undertook this analysis to determine if early changes in biochemical markers with teriparatide therapy predict subsequent increases in BMD.<\/jats:p>\n               <jats:p>Materials and Methods: In the Fracture Prevention Trial, 1637 postmenopausal women with osteoporosis were randomized to receive daily, self-administered, subcutaneous injections of placebo, teriparatide 20 \u03bcg\/day, or teriparatide 40 \u03bcg\/day. Serum concentrations of two bone formation markers (bone-specific alkaline phosphatase [bone ALP] and the carboxy-terminal extension peptide of procollagen type 1 [PICP]) and urinary concentrations of two bone resorption markers (free deoxypyridinoline [DPD] and N-terminal telopeptide [NTX]) were assessed in a trial population subset (n = 520) at baseline and at 1, 3, 6, and 12 months. We also assessed serum concentrations of another bone formation marker, the amino-terminal extension peptide of procollagen type 1 (PINP), in a subset of 771 women at baseline and 3 months. Lumbar spine (LS) BMD was measured by DXA at baseline and 18 months. Femoral neck BMD was measured at baseline and 12 months.<\/jats:p>\n               <jats:p>Results and Conclusion: Baseline bone turnover status correlated positively and significantly with BMD response. The highest correlations occurred for the LS BMD response to teriparatide 20 \u03bcg\/day. Among all studied biochemical markers, increases in PICP at 1 month and PINP at 3 months correlated best with increases in LS BMD at 18 months (0.65 and 0.61, respectively; p &amp;lt; 0.05). The relationships between these two biochemical markers and the LS BMD response were stronger than the corresponding relationships for the femoral neck BMD response. Using receiver operator curve analysis, we determined that the increases in PICP at 1 month and PINP at 3 months were the most sensitive and accurate predictors of the LS BMD response.<\/jats:p>","DOI":"10.1359\/jbmr.050105","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T08:40:51Z","timestamp":1146127251000},"page":"962-970","source":"Crossref","is-referenced-by-count":267,"title":["Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With Osteoporosis"],"prefix":"10.1093","volume":"20","author":[{"given":"Peiqi","family":"Chen","sequence":"first","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie H","family":"Satterwhite","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo A","family":"Licata","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism, The Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Michael","family":"Lewiecki","sequence":"additional","affiliation":[{"name":"New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien A","family":"Sipos","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek M","family":"Misurski","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B","family":"Wagman","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024013019242285200_bib1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S8756-3282(99)00087-3","article-title":"A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover","volume":"24","author":"Garnero","year":"1999","journal-title":"Bone"},{"key":"2024013019242285200_bib2","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1359\/jbmr.1997.12.7.1083","article-title":"Relationship of bone turnover to bone density and fractures","volume":"12","author":"Melton","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2024013019242285200_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/jbmr.5650110307","article-title":"Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024013019242285200_bib4","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/jbmr.5650090916","article-title":"Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: Results of a pilot study","volume":"9","author":"Seibel","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024013019242285200_bib5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1365-2265.1994.tb02512.x","article-title":"Urinary excretion of pyridinium cross-links in healthy women; the long-term effects of menopause and oestrogen\/progesterone therapy","volume":"40","author":"Schlemmer","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024013019242285200_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF01623829","article-title":"Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption","volume":"3","author":"Eastell","year":"1993","journal-title":"Osteoporos Int"},{"key":"2024013019242285200_bib7","first-page":"2363","article-title":"Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study","volume":"84","author":"Ravn","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019242285200_bib8","first-page":"237","article-title":"Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women","volume":"24","author":"Ravn","year":"1999","journal-title":"Alendronate Osteoporosis Prevention Study Group. Bone"},{"key":"2024013019242285200_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9343(96)00387-7","article-title":"Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density","volume":"102","author":"Chesnut","year":"1997","journal-title":"Am J Med"},{"key":"2024013019242285200_bib10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S8756-3282(00)00271-4","article-title":"Monitoring individual response to hormone replacement therapy with bone markers","volume":"26","author":"Delmas","year":"2000","journal-title":"Bone"},{"key":"2024013019242285200_bib11","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","article-title":"Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial","volume":"13","author":"Greenspan","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2024013019242285200_bib12","doi-asserted-by":"crossref","first-page":"197S","DOI":"10.1016\/8756-3282(95)00502-1","article-title":"Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy","volume":"18","author":"Riggs","year":"1996","journal-title":"Bone"},{"key":"2024013019242285200_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019242285200_bib14","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s001980070111","article-title":"Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis","volume":"11","author":"Lane","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024013019242285200_bib15","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jama.280.12.1067","article-title":"Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1\u201334): A randomized controlled trial","volume":"280","author":"Finkelstein","year":"1998","journal-title":"JAMA"},{"key":"2024013019242285200_bib16","first-page":"3069","article-title":"Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers","volume":"85","author":"Kurland","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019242285200_bib17","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"2024013019242285200_bib18","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1\u201334) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"key":"2024013019242285200_bib19","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1002\/(SICI)1097-0258(19970830)16:16<1889::AID-SIM607>3.0.CO;2-V","article-title":"Comparative calibration without a gold standard","volume":"16","author":"Lu","year":"1997","journal-title":"Stat Med"},{"key":"2024013019242285200_bib20","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/jbmr.5650110510","article-title":"Dual X-ray absorptiometry quality control: Comparison of visual examination and process-control charts","volume":"11","author":"Lu","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024013019242285200_bib21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","article-title":"The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis","volume":"18","author":"Marcus","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019242285200_bib22","first-page":"1811","article-title":"Evaluation of biochemical markers of bone formation and resorption as early indicators of bone mineral density response to LY333334 [recombinant human parathyroid hormone (1\u201334)] therapy","volume":"2","author":"Heathman","year":"2000","journal-title":"AAPS PharmSci"},{"key":"2024013019242285200_bib23","author":"Krege","year":"2003"},{"key":"2024013019242285200_bib24","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s001980170020","article-title":"Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis","volume":"12","author":"Bjarnason","year":"2001","journal-title":"Osteoporos Int"},{"key":"2024013019242285200_bib25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bone.2003.10.004","article-title":"Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk","volume":"34","author":"Reginster","year":"2004","journal-title":"Bone"},{"key":"2024013019242285200_bib26","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1359\/JBMR.0301243","article-title":"Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk","volume":"19","author":"Sarkar","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024013019242285200_bib27","first-page":"S521","article-title":"Reduction in bone turnover predicts hip, non-spine, and vertebral fracture in alendronate treated women: The Fracture Intervention Trial","volume":"13","author":"Bauer","year":"2004","journal-title":"Osteoporos Int"},{"key":"2024013019242285200_bib28","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2FJBMR.050105","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/20\/6\/962\/56479473\/5650200610.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/20\/6\/962\/56479473\/5650200610.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:08:51Z","timestamp":1710342531000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/20\/6\/962-970\/7593287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,1]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2005,6,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.050105","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,6,1]]},"published":{"date-parts":[[2005,6,1]]}}}